Hedge Fund - OrbiMed Advisors

Stocks in the biotechnology industry have been very active as of late, with companies' shares registering significant gains.

According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by about...

Samuel Islay's Orbimed Advisors has revealed its equity portfolio as of end of 2014, in a recent filing with the Securities and Exchange Commission.

Samuel Isaly’s Orbimed Advisors has taken an activist stake in the recently listed Ascendis Pharma A/S (NASDAQ:ASND), an early-stage drug company working on a novel method of delivering new and existing...

Samuel Isaly's healthcare-focused fund Orbimed Advisors has disclosed a new position in Sientra Inc (NASDAQ:SIEN), a company that just has gone public.

Altisource Asset Management Corp (NYSEMKT:AAMC) and Affimed Therapeutics BV (NASDAQ:AFMD) felt hedge funds’ bullishness lately.

As a new filing with the Securities and Exchange Commission showed today, Samuel Isaly's Orbimed Advisors have trimmed its exposure to Relypsa Inc (NASDAQ:RLYP).

Orbimed Advisors, led by Samuel Isaly, recently published its 13F filing with the U.S. Securities and Exchange Commission.

Orbimed Advisors, led by Samuel Isaly, has disclosed cutting its position in Intercept Pharmaceuticals Inc. (NASDAQ:ICPT).